AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pasithea Therapeutics Updates Conference Presentation Timing
ByAinvest
Friday, Aug 29, 2025 8:40 am ET1min read
Pasithea Therapeutics Corp has announced a change in the time of its management presentation at the H.C. Wainwright 27th Annual Global Investment Conference to Monday, September 8, at 5:00 PM Eastern Time. CEO Dr. Tiago Reis Marques will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event. The presentation will be webcast and can be registered for. The company is currently testing its lead drug candidate, PAS-004, in a Phase 1 clinical trial in advanced cancer patients and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1-associated plexiform neurofibromas.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced a change in the time of its management presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation, originally scheduled for September 10, 2025, at 2:30 PM ET, has been rescheduled to Monday, September 8, 2025, at 5:00 PM Eastern Time [1][2].CEO Dr. Tiago Reis Marques will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event. The presentation will be webcast and can be registered for via the event's website.
Pasithea Therapeutics is a clinical-stage biotechnology company focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839) and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565) [1][2].
The conference, taking place September 8-10, 2025, in New York City, provides an opportunity for investors and financial professionals to learn more about the company's progress and future plans. The rescheduling of the presentation allows for more engagement with attendees and potential investors.
References:
[1] https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-shsx7jet6h2l.html
[2] https://www.biospace.com/press-releases/pasithea-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet